Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin (2016 - 2025)

Historic Net Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 11.53%.

  • Ani Pharmaceuticals' Net Margin rose 281000.0% to 11.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.72%, marking a year-over-year increase of 62900.0%. This contributed to the annual value of 3.28% for FY2024, which is 68000.0% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Net Margin stood at 11.53% for Q3 2025, which was up 281000.0% from 3.85% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Net Margin ranged from a high of 12.95% in Q1 2024 and a low of 39.93% during Q4 2021
  • For the 5-year period, Ani Pharmaceuticals' Net Margin averaged around 6.28%, with its median value being 1.95% (2024).
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -336100bps in 2021, then soared by 349900bps in 2022.
  • Ani Pharmaceuticals' Net Margin (Quarter) stood at 39.93% in 2021, then surged by 88bps to 4.93% in 2022, then surged by 112bps to 0.57% in 2023, then plummeted by -1085bps to 5.61% in 2024, then skyrocketed by 306bps to 11.53% in 2025.
  • Its Net Margin stands at 11.53% for Q3 2025, versus 3.85% for Q2 2025 and 7.75% for Q1 2025.